- Antibody drug conjugates (ADCs), which combine the targeting capabilities of monoclonal antibodies with the potent cell-killing effect of cytotoxic drugs, are becoming a critical class of therapeutics in oncology across the Asia-Pacific region due to their enhanced efficacy, targeted delivery, and reduced systemic toxicity
- The rising demand for ADCs is primarily driven by the increasing cancer prevalence, improving healthcare infrastructure, and growing access to advanced biopharmaceuticals across emerging economies such as China and India
- China dominated the Asia-Pacific antibody drug conjugates (ADC) market with the largest revenue share of 48.1% in 2024, supported by accelerated regulatory approvals, extensive clinical research activities, and strategic partnerships between domestic firms and global biotech players focusing on novel ADC pipelines
- Japan is expected to witnessing fastest growth in antibody drug conjugates (ADC) market, propelled by high healthcare expenditure, well-established pharmaceutical industries, and rising patient awareness regarding targeted cancer therapies
- Breast cancer segment dominated the Asia-Pacific antibody drug conjugates (ADC) market, with a market share of 40.2% in the Asia-Pacific antibody drug conjugates (ADC) market in 2024, owing to the high incidence rate, increasing diagnosis rates, and the presence of several approved ADC therapies targeting HER2-positive breast cancer
